CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
Summary: Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription factor CREB5 confers enzalutamide resistance in an o...
Váldodahkkit: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Materiálatiipa: | Artihkal |
Giella: | English |
Almmustuhtton: |
Elsevier
2019-11-01
|
Ráidu: | Cell Reports |
Liŋkkat: | http://www.sciencedirect.com/science/article/pii/S2211124719313828 |